News
LAMA2-MD consortium meetings
In september 2023 we started with the LAMA2-MD consortium meetings for researchers, clinicians, companies and patients and their representatives. The…
Medical knowledge
-
![]()
News
-
![]()
Medical knowledge
Prof. Durbeej on pathological mechanisms and potential therapies for LAMA2-CMD
Professor Dr Madeleine Durbeej of Lund University, Sweden provided an overview of existing research on the mechanisms of LAMA2-CMD and…
-
![]()
Medical knowledge
Dr Camelo reports on a Brazilian LAMA2-CMD longitudinal study
Dr Clara Camelo presented key findings from a longitudinal study of Brazilian patients to better understand the correlation between genetic…
-
![]()
Medical knowledge
A Linker Protein Gene Therapy Approach For LAMA2-CMD
Dr. Yurchenco (NJ, USA) and Dr. Rüegg (Basel, Switzerland) are collaborating with Santhera Pharmaceuticals to develop an emerging gene therapy…
-
![]()
Medical knowledge
Dr. Dwi Kemaladewi On A Promising New Therapeutic Strategy For LAMA2-CMD
Dr. Dwi Kemaladewi is playing a a key role in developing a novel therapeutic approach that has opened new treatment…
-
![]()
Medical knowledge
Prothelia: Developing A Protein Replacement Therapy For LAMA2-CMD
Steven Axon is the CEO of Prothelia, a biopharmaceutical company based in Massachusetts, USA, committed to developing a promising new…
The driving forces behind Lama2.com
View all partners
